1057 related articles for article (PubMed ID: 26802026)
61. Intrinsic resistance to the MEK1/2 inhibitor AZD6244 (ARRY-142886) is associated with weak ERK1/2 signalling and/or strong PI3K signalling in colorectal cancer cell lines.
Balmanno K; Chell SD; Gillings AS; Hayat S; Cook SJ
Int J Cancer; 2009 Nov; 125(10):2332-41. PubMed ID: 19637312
[TBL] [Abstract][Full Text] [Related]
62. Autophagy mediates cytotoxicity of human colorectal cancer cells treated with garcinielliptone FC.
Won SJ; Yen CH; Lin TY; Jiang-Shieh YF; Lin CN; Chen JT; Su CL
J Cell Physiol; 2018 Jan; 233(1):497-505. PubMed ID: 28294332
[TBL] [Abstract][Full Text] [Related]
63. Combination of antibodies directed against different ErbB3 surface epitopes prevents the establishment of resistance to BRAF/MEK inhibitors in melanoma.
Fattore L; Malpicci D; Marra E; Belleudi F; Noto A; De Vitis C; Pisanu ME; Coluccia P; Camerlingo R; Roscilli G; Ribas A; Di Napoli A; Torrisi MR; Aurisicchio L; Ascierto PA; Mancini R; Ciliberto G
Oncotarget; 2015 Sep; 6(28):24823-41. PubMed ID: 26208478
[TBL] [Abstract][Full Text] [Related]
64. Receptor tyrosine kinases exert dominant control over PI3K signaling in human KRAS mutant colorectal cancers.
Ebi H; Corcoran RB; Singh A; Chen Z; Song Y; Lifshits E; Ryan DP; Meyerhardt JA; Benes C; Settleman J; Wong KK; Cantley LC; Engelman JA
J Clin Invest; 2011 Nov; 121(11):4311-21. PubMed ID: 21985784
[TBL] [Abstract][Full Text] [Related]
65. Blocking autophagic flux enhances matrine-induced apoptosis in human hepatoma cells.
Wang L; Gao C; Yao S; Xie B
Int J Mol Sci; 2013 Nov; 14(12):23212-30. PubMed ID: 24287900
[TBL] [Abstract][Full Text] [Related]
66. Alterations of mTOR signaling impact metabolic stress resistance in colorectal carcinomas with BRAF and KRAS mutations.
Fritsche-Guenther R; Zasada C; Mastrobuoni G; Royla N; Rainer R; Roßner F; Pietzke M; Klipp E; Sers C; Kempa S
Sci Rep; 2018 Jun; 8(1):9204. PubMed ID: 29907857
[TBL] [Abstract][Full Text] [Related]
67. Novel PI3K/Akt/mTOR signaling inhibitor, W922, prevents colorectal cancer growth via the regulation of autophagy.
Wang J; Liang D; Zhang XP; He CF; Cao L; Zhang SQ; Xiao X; Li SJ; Cao YX
Int J Oncol; 2021 Jan; 58(1):70-82. PubMed ID: 33367926
[TBL] [Abstract][Full Text] [Related]
68. Selective Targeting of CTNBB1-, KRAS- or MYC-Driven Cell Growth by Combinations of Existing Drugs.
Uitdehaag JC; de Roos JA; van Doornmalen AM; Prinsen MB; Spijkers-Hagelstein JA; de Vetter JR; de Man J; Buijsman RC; Zaman GJ
PLoS One; 2015; 10(5):e0125021. PubMed ID: 26018524
[TBL] [Abstract][Full Text] [Related]
69. Resistance to selective BRAF inhibition can be mediated by modest upstream pathway activation.
Su F; Bradley WD; Wang Q; Yang H; Xu L; Higgins B; Kolinsky K; Packman K; Kim MJ; Trunzer K; Lee RJ; Schostack K; Carter J; Albert T; Germer S; Rosinski J; Martin M; Simcox ME; Lestini B; Heimbrook D; Bollag G
Cancer Res; 2012 Feb; 72(4):969-78. PubMed ID: 22205714
[TBL] [Abstract][Full Text] [Related]
70. Crenolanib Regulates ERK and AKT/mTOR Signaling Pathways in RAS/BRAF-Mutated Colorectal Cancer Cells and Organoids.
Fujino S; Miyoshi N; Ito A; Yasui M; Ohue M; Ogino T; Takahashi H; Uemura M; Matsuda C; Mizushima T; Doki Y; Eguchi H
Mol Cancer Res; 2021 May; 19(5):812-822. PubMed ID: 33579816
[TBL] [Abstract][Full Text] [Related]
71. BRaf and MEK inhibitors differentially regulate cell fate and microenvironment in human hepatocellular carcinoma.
Breunig C; Mueller BJ; Umansky L; Wahl K; Hoffmann K; Lehner F; Manns MP; Bantel H; Falk CS
Clin Cancer Res; 2014 May; 20(9):2410-23. PubMed ID: 24573550
[TBL] [Abstract][Full Text] [Related]
72. w09, a novel autophagy enhancer, induces autophagy-dependent cell apoptosis via activation of the EGFR-mediated RAS-RAF1-MAP2K-MAPK1/3 pathway.
Zhang P; Zheng Z; Ling L; Yang X; Zhang N; Wang X; Hu M; Xia Y; Ma Y; Yang H; Wang Y; Liu H
Autophagy; 2017 Jul; 13(7):1093-1112. PubMed ID: 28513279
[TBL] [Abstract][Full Text] [Related]
73. Inhibition of autophagy enhances apoptosis induced by the PI3K/AKT/mTor inhibitor NVP-BEZ235 in renal cell carcinoma cells.
Li H; Jin X; Zhang Z; Xing Y; Kong X
Cell Biochem Funct; 2013 Jul; 31(5):427-33. PubMed ID: 23086777
[TBL] [Abstract][Full Text] [Related]
74. Inhibition of the phosphatidylinositol 3-kinase/Akt/mammalian target of rapamycin pathway but not the MEK/ERK pathway attenuates laminin-mediated small cell lung cancer cellular survival and resistance to imatinib mesylate or chemotherapy.
Tsurutani J; West KA; Sayyah J; Gills JJ; Dennis PA
Cancer Res; 2005 Sep; 65(18):8423-32. PubMed ID: 16166321
[TBL] [Abstract][Full Text] [Related]
75. Targeting CDK1 and MEK/ERK Overcomes Apoptotic Resistance in BRAF-Mutant Human Colorectal Cancer.
Zhang P; Kawakami H; Liu W; Zeng X; Strebhardt K; Tao K; Huang S; Sinicrope FA
Mol Cancer Res; 2018 Mar; 16(3):378-389. PubMed ID: 29233910
[TBL] [Abstract][Full Text] [Related]
76.
Jiménez-Mora E; Gallego B; Díaz-Gago S; Lasa M; Baquero P; Chiloeches A
Int J Mol Sci; 2021 Jun; 22(11):. PubMed ID: 34204950
[TBL] [Abstract][Full Text] [Related]
77. Differential activity of MEK and ERK inhibitors in BRAF inhibitor resistant melanoma.
Carlino MS; Todd JR; Gowrishankar K; Mijatov B; Pupo GM; Fung C; Snoyman S; Hersey P; Long GV; Kefford RF; Rizos H
Mol Oncol; 2014 May; 8(3):544-54. PubMed ID: 24476679
[TBL] [Abstract][Full Text] [Related]
78. The combination of RAD001 and MK-2206 exerts synergistic cytotoxic effects against PTEN mutant gastric cancer cells: involvement of MAPK-dependent autophagic, but not apoptotic cell death pathway.
Ji D; Zhang Z; Cheng L; Chang J; Wang S; Zheng B; Zheng R; Sun Z; Wang C; Zhang Z; Liu R; Zhang X; Liu X; Wang X; Li J
PLoS One; 2014; 9(1):e85116. PubMed ID: 24416349
[TBL] [Abstract][Full Text] [Related]
79. Genotype-dependent sensitivity of uveal melanoma cell lines to inhibition of B-Raf, MEK, and Akt kinases: rationale for personalized therapy.
Mitsiades N; Chew SA; He B; Riechardt AI; Karadedou T; Kotoula V; Poulaki V
Invest Ophthalmol Vis Sci; 2011 Sep; 52(10):7248-55. PubMed ID: 21828154
[TBL] [Abstract][Full Text] [Related]
80. Horizontal Combination of MEK and PI3K/mTOR Inhibition in BRAF Mutant Tumor Cells with or without Concomitant PI3K Pathway Mutations.
Rittler D; Molnár E; Baranyi M; Garay T; Hegedűs L; Aigner C; Tóvári J; Tímár J; Hegedűs B
Int J Mol Sci; 2020 Oct; 21(20):. PubMed ID: 33081092
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]